Compounded GLP-1/GIP (Tirzepatide)
US$ 27.20
retatrutide clinical development safety trials A new clinical trial from Eli Lilly and Company suggests its experimental Phase III retatrutide study demonstrates
Description
Breakthrough discoveries require vision as well as courage
Third-party social proof is thin
Tirzepatide is a newer medication used to support weight loss, especially in women who are struggling despite diet and exercise
they may soon be used to treat liver disease, cardiovascular conditions, sleep apnea and even reduce cancer risk
[1] The MHRA also notes that gastrointestinal side effects can sometimes lead to severe dehydration requiring hospital care
